Clinical Trials Logo
  1. Home
  2. Uterine Carcinosarcoma
  3. NCT01367301

Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer

Uterine Carcinosarcoma Clinical Trial

Official title:
A Pilot Trial of Radiation Therapy "Sandwiched" Between Paclitaxel and Carboplatin in Patients With Uterine Carcinosarcoma

Clinical Trial Summary

This pilot clinical trial studies radiation therapy, paclitaxel, and carboplatin in treating patients with uterine cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or stopping them from dividing. Giving radiation with chemotherapy may kill more tumor cells.

Clinical Trial Description

PRIMARY OBJECTIVES: I. To assess the one year recurrence-free survival in patients with uterine carcinosarcoma treated with "sandwich" therapy-including defining the patterns of recurrence in patients with carcinosarcoma who were treated with this regimen. II. To evaluate the toxicity and tolerability of pelvic radiation "sandwiched" between cycles of paclitaxel/carboplatin chemotherapy in patients with uterine carcinosarcoma. III. To correlate surrogate endpoint biomarkers with progression-free survival and prognosis. OUTLINE: CHEMOTHERAPY (weeks 1-9, 14-22): Patients receive paclitaxel intravenously (IV) over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 3 courses during weeks 1-9 and 14-22. RADIATION THERAPY (weeks 8-16): Patients undergo external beam pelvic radiation therapy once a day, 5 days a week for 5 weeks during weeks 8-13. Patients then undergo high dose radiation (HDR) brachytherapy or intensity-modulated radiation therapy (IMRT) once weekly during weeks 14-16. After completion of study treatment, patients are followed up every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01367301
Study type Interventional
Source Albert Einstein College of Medicine
Contact
Status Terminated
Phase N/A
Start date July 8, 2011
Completion date August 15, 2018
View Details
See also
  Status Clinical Trial Phase
Completed NCT01010126 - Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Phase 2
Completed NCT01168232 - Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer Phase 2
Completed NCT00390234 - Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma Phase 2
Completed NCT00245102 - Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Phase 2
Completed NCT00025506 - Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus Phase 2
Recruiting NCT05902988 - A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer Phase 1/Phase 2
Recruiting NCT05619913 - EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma Phase 2
Completed NCT00687687 - Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma Phase 2
Completed NCT00114218 - Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer Phase 2
Withdrawn NCT03902379 - Web-Based Coping and Communication Skills Intervention in Improving Psychological Adaptation in Patients With Gynecological Cancer N/A
Completed NCT03694262 - The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib) Phase 2
Completed NCT01247571 - Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer Phase 2
Terminated NCT01061606 - Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus Phase 2
Completed NCT00075400 - Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer Phase 2
Completed NCT00659360 - AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Phase 2
Completed NCT00238121 - Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer Phase 2
Recruiting NCT05147558 - A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine Carcinosarcoma Phase 2
Active, not recruiting NCT00954174 - Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Phase 3
Completed NCT00478426 - Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Phase 2
Recruiting NCT05229601 - A Study of HFB301001 in Adult Patients With Advanced Solid Tumors Phase 1